Skip to main content

BioAtla, Inc.

corporate_fare Company Profile

BioAtla, Inc.

BCAB·OTC·Life Sciences·CIK 0001826892

We are a clinical-stage biopharmaceutical company focused on developing a new class of highly specific and selective antibody-based treatments for solid tumor cancers. Our conditionally active biologics, or CABs, utilize our proprietary discoveries in tumor biology to target known tumor antigens that have previously been challenging to address. These CAB therapeutic candidates exploit the characteristic acidic pH of the tumor microenvironment, which differs from healthy tissue. We design our antibodies to selectively bind to targets on cancer cells under acidic pH conditions, but not on targets in normal tissues. Our strategy aims to achieve the necessary targeting and potency for cancer cell destruction while eliminating or significantly reducing on-target, off-tumor toxicity, a common challenge with existing cancer therapies. The enhanced selectivity of our CAB technology is intended to improve the benefit-risk ratio for patients and allows for desired drug levels as monotherapy or in multi-targeted or combination therapies. The combination of reversible binding with the selective, precision capability of our CAB technology enables both increased antibody potency and reduced toxicity. Our proprietary CAB technology has the potential to transform antibody-based cancer therapy. Our goal is to develop well-tolerated, novel cancer therapies that provide cures or extended survival to improve patients' quality of life. Our CAB technology's broad applicability allows us to develop various product candidate modalities, including monoclonal antibodies, antibody-drug conjugates (ADCs), T cell-engaging bispecific antibodies, and chimeric antigen receptor T cells (CAR-T cells).

BioAtla, Inc. (OTC:BCAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for BCAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 20 rated 8 or above. Recent SEC coverage for BCAB spans 10-Q, S-1, 8-K, DEF 14A.

Recent high-impact activity:

  • BioAtla 10-Q: $0.6M Cash Left, Going Concern Reaffirmed, $4.9M Impairment
  • BioAtla Registers 8.18M Shares for New $40M Yorkville Standby Equity Facility
  • BioAtla Signs $40M Yorkville Equity Line, Replacing $15M SEPA
  • BioAtla Delisting Confirmed: Nasdaq Trading Suspension Set for August 31
  • BioAtla Flags Going Concern with $1.5M Cash, Pauses Enrollment

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$59.61M
Diluted EPS
-$1.01
Op. Cash Flow
-$48.2M
Operating Income
-$59.3M
Cash & Equivalents
$7.12M
Debt / Equity
0.00×
Shares Outstanding
63.46M sh
Source: 10-K · filed 2026-03-31 · accession 0001193125-26-134499

Short Interest & Short Volume

6.22 days to cover

FINRA reported short interest of 71,975 shares in BCAB as of the October 30, 2026 settlement, a 1.2% decrease from the prior period — about 6.2 days to cover at its recent average daily volume. On November 20, 2026, 23.4% of BCAB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)71,975 shares as of October 30, 2026
Change vs prior period▼ 1.2%
Days to cover6.22 at avg daily volume of 11,577
Daily short volume (FINRA facilities)23.4% of 3,802 shares on November 20, 2026
5-day average short volume47.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for BCAB, detected from its recent SEC filings.

1 shelf registration

New $40M Yorkville Standby Facility · 8.18M Shares Registered for Resale

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$1.55 +20.16% today
52-week range · as of 2026-11-16 $1.07 – $3575
Market cap
$2.59M
Volume
3.8K (0.6× avg)
3-mo avg 6.7K
Live data · 2026-11-21 02:02 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed BCAB - Latest Insights

BCAB
Nov 16, 2026, 9:00 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.56
Real-time Price: $1.55 info
Change: -$0.010 (-0.64%) info
Market Cap: $2.586M info
BCAB
Oct 19, 2026, 9:42 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $1.31
Real-time Price: $1.55 info
Change: +$0.240 (+18%) info
Market Cap: $2.586M info
BCAB
Oct 19, 2026, 9:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.31
Real-time Price: $1.55 info
Change: +$0.240 (+18%) info
Market Cap: $2.586M info
BCAB
Aug 28, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.25
Real-time Price: $1.55 info
Change: -$1.70 (-52%) info
Market Cap: $2.586M info
BCAB
Aug 13, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.60
Real-time Price: $1.55 info
Change: -$2.05 (-57%) info
Market Cap: $2.586M info
BCAB
Jun 03, 2026, 4:07 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $3.40
Real-time Price: $1.55 info
Change: -$1.85 (-54%) info
Market Cap: $2.586M info
BCAB
May 15, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.27
Real-time Price: $1.55 info
Change: -$2.72 (-64%) info
Market Cap: $2.586M info
BCAB
May 15, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.27
Real-time Price: $1.55 info
Change: -$2.72 (-64%) info
Market Cap: $2.586M info
BCAB
Apr 02, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.1292
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Apr 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1333
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Mar 31, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
10
Price at Filing: $0.1306
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Mar 31, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1306
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Mar 23, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1749
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Mar 02, 2026, 7:42 AM EST
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $0.2316
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Mar 02, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2316
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Feb 09, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1502
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Feb 06, 2026, 5:02 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2194
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Jan 30, 2026, 5:13 PM EST
Filing Type: PREM14A
Importance Score:
9
Price at Filing: $0.2571
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Jan 30, 2026, 4:41 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2708
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Jan 16, 2026, 4:05 PM EST
Filing Type: S-3
Importance Score:
9
Price at Filing: $0.3338
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets